Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Next Previous
X
Search
Trial Profile

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Copanlisib (Primary)
  • Indications Anaplastic large cell lymphoma; B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CHRONOS-1
  • Sponsors Bayer; Bayer HealthCare

    • Most Recent Events

    • 26 Apr 2024 This trial has been completed in Italy according to European Clinical Trials Database record.
    • 06 Jul 2023 This trial has been discontinued in Denmark (End Date: 18 May 2023), according to European Clinical Trials Database record.
    • 12 Jun 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top